Neither Ativan nor Xanax Should Be Used for Sleep
Both lorazepam (Ativan) and alprazolam (Xanax) are inappropriate choices for treating insomnia and should be avoided entirely. Major clinical practice guidelines explicitly advise against using any benzodiazepines for chronic insomnia disorder because their harms substantially outweigh benefits 1, 2.
Why Both Drugs Are Problematic
The 2019 VA/DoD and 2016 American College of Physicians guidelines reached the same conclusion: benzodiazepines improve sleep metrics (efficiency, onset latency, total sleep time) compared to placebo, but their adverse effect profile is unacceptable 1, 2. The widely recognized harms include:
- Dependency and addiction risk with potential for diversion
- Falls and cognitive impairment, particularly dangerous in older adults
- Respiratory depression in patients with sleep apnea, obesity hypoventilation, or neuromuscular disease
- Serious injuries from complex sleep behaviors
- Dementia risk and fractures from observational data 2
Specific Problems with Each Drug
Alprazolam (Xanax) - Worse Choice
Research demonstrates alprazolam loses approximately 40% of its sleep efficacy after just one week of nightly use 3. The drug causes:
- Rapid tolerance development within 7 nights
- Rebound insomnia of comparable magnitude to initial improvement upon withdrawal 3
- Disinhibition with inappropriate emotional expression 3
- Severe psychomotor impairment affecting driving and coordination 4
Lorazepam (Ativan) - Also Inappropriate
While lorazepam maintains efficacy slightly better than alprazolam, it still causes 5, 6:
- Marked rebound insomnia on the third withdrawal night, several times worse than the initial sleep improvement
- Rebound anxiety during withdrawal 6
- Severe hangover effects and impaired daytime functioning for the first 3 days 6
- Anterograde amnesia and confusion episodes 5, 6
Real-world data confirms lorazepam is the most overprescribed hypnotic (36% of all prescriptions), with 54% of insomnia cases showing more prescription refills than medical consultations, indicating problematic automatic renewals 7.
What to Use Instead
First-line treatment: Cognitive behavioral therapy for insomnia (CBT-I) is the only recommended initial approach, providing effectiveness without the serious adverse events of pharmacotherapy 1, 2.
If pharmacotherapy is necessary (short-term only, 4-5 weeks maximum):
- Low-dose doxepin (3-6 mg) - improves sleep efficiency without benzodiazepine risks 1
- Nonbenzodiazepine BZRAs (zolpidem, eszopiclone) - better safety profile than benzodiazepines, though still carry FDA warnings about complex sleep behaviors 1
- Dual orexin receptor antagonists (daridorexant) - can be discontinued abruptly without withdrawal symptoms 8
- Melatonin receptor agonists - minimal risk profile 9
Critical Pitfall to Avoid
The FDA approves hypnotics for only 4-5 weeks of use. Patients with insomnia persisting beyond 7-10 days of treatment require further evaluation, not continued benzodiazepine prescriptions 2. The practice of automatic refills without follow-up, documented in 54% of cases 7, perpetuates dependency and exposes patients to long-term harms without proven long-term efficacy.
Bottom line: If forced to choose between these two benzodiazepines, neither is acceptable. Lorazepam has slightly less rapid tolerance development than alprazolam 4, 3, but this marginal difference is irrelevant given that both drugs are contraindicated for insomnia treatment by major guidelines 1, 2.